Reported Sunday, Bluebird Bio Highlights 9-Year Data For LYFGENIA Gene Therapy: Sustained Benefits In Sickle Cell Disease Patients At ASH 2024
Reported Sunday, Bluebird Bio Highlights 9-Year Data For LYFGENIA Gene Therapy: Sustained Benefits In Sickle Cell Disease Patients At ASH 2024
週日報道，bluebird bio 在2024年ASH大會上強調了LYFGENIA基因療法的9年數據：在鐮狀細胞病患者中持續獲得益處
- Stable production of anti-sickling adult hemoglobin (HBAT87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring potentially transformative and durable clinical impact
- Results from first and only focused analysis of patients with sickle cell disease with a history of overt or silent stroke (n=27) show no stroke recurrence through 9 years of follow-up (n=2)
- 穩定生產抗鐮刀型成人血紅蛋白 (HBAT87Q)，並在所有可評估患者 (n=38) 中消除或顯著減少 vaso-occlusive 事件，持續到最後隨訪，強調了可能的變革性和持久臨床影響。
- 對有明顯或隱性中風病史的鐮狀細胞病患者 (n=27) 的首次也是唯一的一項重點分析結果顯示，經過9年的隨訪 (n=2) 沒有中風復發。
資訊熱榜
更新時間